市場調查報告書
商品編碼
1494878
到 2030 年藥用玻璃安瓿市場預測:按產品類型、類型、產能、應用、最終用戶和地區進行的全球分析Pharmaceutical Glass Ampoules Market Forecasts to 2030 - Global Analysis By Product Type, Type, Capacity, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2024 年全球藥用玻璃安瓿市場規模為 148 億美元,預計在預測期內複合年成長率為 8.9%,到 2030 年將達到 247 億美元。
藥用玻璃安瓿是由玻璃製成的密封管瓶,用於封裝和儲存液體藥物,特別是注射用藥物。這些安瓿通常由優質硼矽酸玻璃製成,具有出色的耐化學性和熱穩定性,確保封裝藥品的純度和穩定性。玻璃材料可防止藥物與容器的相互作用並保持藥物的功效和安全性。藥用玻璃安瓿廣泛應用於醫院和臨床環境,對於安全有效地傳遞疫苗、注射和其他關鍵藥物至關重要。
根據 CNN 和 OWID 報導,截至 2023 年 3 月 20 日,全球已接種了約 130 億劑 COVID-19 疫苗,其中美國接種了約 6.72 億劑。
藥品需求增加
藥品中單劑量包裝的成長趨勢與玻璃安瓿的優勢完全一致。單劑量包裝可最大限度地降低藥物污染風險並確保劑量準確。玻璃安瓿為這個不斷成長的市場提供了一個方便、安全的解決方案。此外,許多藥品,特別是那些源自生物技術或含有敏感成分的藥品,需要包裝提供出色的保護,以防止水分、空氣和劣化等因素的影響。具有優異阻隔性能和化學惰性的玻璃安瓿是這種敏感藥品的理想選擇,並正在推動市場成長。
製造成本高
製造玻璃安瓿需要複雜的製程和高品質的硼矽酸玻璃,而且價格昂貴。對純度和安全性的嚴格監管要求進一步加劇了這些成本,這需要先進的技術和嚴格的品管措施。因此,整體製造成本明顯較高。小型製藥公司,尤其是新興市場的小型製藥公司,可能難以滿足這些高成本,這限制了注射藥物的生產和分銷並阻礙了市場成長。
環保考量
對永續性的日益關注為藥用玻璃安瓿市場創造了機會。玻璃是一種可回收材料,使其成為比某些塑膠包裝更環保的選擇。隨著消費者和醫療保健提供者的環保意識越來越強,對玻璃安瓿等永續包裝解決方案的需求可能會增加。因此,玻璃安瓿提供了一種展示對環境責任的承諾的方式,並有可能吸引具有環保意識的客戶。
自動化可能性有限
玻璃安瓿製造涉及複雜的流程,難以完全自動化,並且嚴重依賴技術純熟勞工進行品管和封裝等精密操作。此外,缺乏自動化會減慢生產速度,阻礙滿足不斷成長的藥品需求的能力,特別是在流行病和健康危機等激增期間。這些低效率可能導致供應鏈中斷和基本藥物交付延遲,從而影響醫療保健提供者和患者。
COVID-19 的影響
疫苗和注射藥物需求的激增導致藥用玻璃安瓿產量增加,以支持大規模免疫宣傳活動和治療行動。然而,全球供應鏈和製造業務的中斷最初成為一個問題,導致供不應求。此外,對疫苗分發和儲存的需求不斷增加,凸顯了可靠、高品質玻璃安瓿的重要性。
預計直管安瓿細分市場在預測期間規模最大
隨著對更安全、更方便的包裝的需求不斷增加,直管安瓿預計在預測期內將以最高銷售量成長。對於希望在藥用玻璃安瓿市場上實現產品差異化的製造商來說,直管安瓿代表著競爭優勢。其獨特的設計和安全性可以吸引尋求創新解決方案的醫療提供者和製藥公司。
中性玻璃安瓿細分市場預計在預測期內複合年成長率最高
中性玻璃安瓿具有優異的耐化學性,使其適合儲存多種藥物配方,包括酸性、鹼性和中性化合物。這種多功能性使製藥公司能夠在各種配方中使用中性玻璃安瓿,從而擴大市場覆蓋範圍。
由於慢性病增加、注射藥物需求增加以及對安全可靠的包裝解決方案的需求有助於市場擴張等因素,預計北美將在預測期內佔據最大的市場佔有率。此外,玻璃製造流程的技術進步、嚴格的監管標準以及主要市場參與企業的存在進一步刺激了市場成長。
隨著中國建立製藥業的標準框架,預計亞太地區在預測期內將保持最高的複合年成長率。國家越來越注重藥品包裝材料在藥品儲存過程中的穩定性以及包裝在使用過程中的安全性。由於玻璃包裝的耐用性、非反應性、透明度、環境相容性和多功能性,製藥公司擴大轉向玻璃包裝。此外,由於醫療保健系統投資增加、研發增加以及藥品成本增加,管瓶的需求量很大。
According to Stratistics MRC, the Global Pharmaceutical Glass Ampoules Market is accounted for $14.8 billion in 2024 and is expected to reach $24.7 billion by 2030 growing at a CAGR of 8.9% during the forecast period. Pharmaceutical glass ampoules are small, sealed vials made from glass, used to contain and preserve liquid medications, especially for injectable purposes. These ampoules are typically made from high-quality borosilicate glass, which offers excellent chemical resistance and thermal stability, ensuring the purity and stability of the contained pharmaceutical products. The glass material prevents interaction between the drug and the container, maintaining the efficacy and safety of the medication. This is widely used in hospitals and clinical settings, pharmaceutical glass ampoules are crucial for delivering vaccines, injectable drugs, and other critical medications safely and effectively.
According to CNN and OWID, as of March 20, 2023, about 13 billion COVID-19 vaccine doses had been administered globally, with the United States accounting for almost 672 million.
Rising Demand for Pharmaceuticals
The growing trend towards single-dose packaging in pharmaceuticals aligns perfectly with the strengths of glass ampoules. Single-dose packaging minimizes the risk of medication contamination and ensures precise dosage administration. Glass ampoules provide a convenient and safe solution for this growing market segment. Moreover many medications, particularly those derived from biotechnology or containing delicate components, require packaging that offers superior protection against factors like moisture, air, and light degradation. Glass ampoules, with their excellent barrier properties and chemical inertness, are ideal for this sensitive drug drives the growth of the market.
High cost of production
Manufacturing glass ampoules involves complex processes and high-quality borosilicate glass, which can be expensive. These costs are further compounded by stringent regulatory requirements for purity and safety, necessitating advanced technology and rigorous quality control measures. As a result, the overall production costs are significantly high. Smaller pharmaceutical companies, particularly in developing regions, might struggle to afford these higher costs, limiting their ability to produce or distribute injectable medications effectively hampers the growth of the market.
Eco-friendly considerations
The growing focus on sustainability presents an opportunity for the pharmaceutical glass ampoule market. Glass is a recyclable material, making it an eco-friendly alternative compared to some plastic packaging options. As consumers and healthcare institutions become more environmentally conscious, the demand for sustainable packaging solutions like glass ampoules could rise. Thus glass ampoules can be a way to showcase a commitment to environmental responsibility, potentially attracting environmentally conscious customers.
Limited automation potential
Manufacturing glass ampoules involves intricate processes that are difficult to fully automate, relying heavily on skilled labor for precision tasks like quality control and sealing. Additionally, the lack of automation leads to slower production rates, hindering the ability to meet the growing demand for pharmaceutical products, especially during surges such as during pandemics or health crises. This inefficiency can result in supply chain disruptions and delays in the delivery of essential medications, impacting healthcare providers and patients.
Covid-19 Impact
The surge in demand for vaccines and injectable medications led to increased production of pharmaceutical glass ampoules to accommodate mass vaccination campaigns and treatment efforts. However, disruptions in global supply chains and manufacturing operations initially posed challenges, resulting in supply shortages. Additionally, heightened focus on vaccine distribution and storage requirements emphasized the importance of reliable and high-quality glass ampoules.
The straight-stem ampoules segment is expected to be the largest during the forecast period
The straight-stem ampoules is expected to be the largest during the forecast period as the demand for safer and more user-friendly packaging grows, straight-stem ampoules offer a competitive advantage for manufacturers looking to differentiate their products in the Pharmaceutical Glass Ampoules market. Their unique design and safety features can attract healthcare providers and pharmaceutical companies seeking innovative solutions.
The neutral glass ampoules segment is expected to have the highest CAGR during the forecast period
The neutral glass ampoules segment is expected to have the highest CAGR during the forecast period owing to the chemical resistance of neutral glass makes it suitable for storing a diverse range of pharmaceutical formulations, including acidic, basic, and neutral compounds. This versatility allows pharmaceutical companies to use neutral glass ampoules for various drug formulations, expanding their market applicability.
North America is projected to hold the largest market share during the forecast period owing to factors such as the increasing prevalence of chronic diseases, rising demand for injectable medications, and the need for secure and reliable packaging solutions contribute to market expansion. Additionally, technological advancements in glass manufacturing processes, stringent regulatory standards, and the presence of key market players further stimulate market growth.
Asia Pacific is projected to hold the highest CAGR over the forecast period as China has established a standard framework for the pharmaceutical industry. The country is increasingly focusing on the stability of pharmaceutical packaging materials during drug storage and the safety of the packaging when used. Pharmaceutical companies increasingly use glass packaging because of its durability, non-reactivity, transparency, eco-friendliness, and versatility. Additionally, glass vials are in high demand due to increasing investment and R&D in healthcare systems and rising drug spending.
Key players in the market
Some of the key players in Pharmaceutical Glass Ampoules market include AAPL Solutions Pvt. Ltd, Accu-Glass LLC, Adit Containers Private Limited, Agrado SA, Birgimefar Group, BOROSIL, CORNING INCORPORATED, Gerresheimer AG, J. Penner Corporation, Kapoor Glass India Pvt. Lt, NIPRO Corporation, Schott AG, SGD SA (SGD Pharma), Shandong Pharmaceutical Glass Co. Ltd, Sm Pack SpA, Stevanato Group SPA, Stoelzle Oberglas GmbH and Zhengchuan Pharmaceutical Packaging
In April 2024, SCHOTT launches pilot projects on glass-ceramics and specialty glass for a more circular economy. The circular economy a joint challenge for policymakers and the specialty glass industry
In March 2024, Stevanato Group Unveils New Plant in Cisterna di Latina for the Production of Pre-Sterilized EZ-fill(R) Syringes and Cartridges, the facility started commercial production in Q4 2023 and houses advanced production lines developed by Stevanato Group for the production of EZ-fill(R) pre-sterilized syringes
In March 2024, Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters' Option to Purchase Additional Ordinary Shares. The total gross proceeds from the Offering, before deducting underwriting discounts and commissions
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.